Hospital

Pirtobrutinib shows promising results in a head-to-head trial against ibrutinib for chronic lymphocytic leukemia (CLL)/small lymphocytic leukemia (SLL).

Luspatercept shows promise in reducing transfusion dependence for myelofibrosis-associated anemia, despite not meeting primary trial end points.

Astegolimab shows promise in reducing chronic obstructive pulmonary disease (COPD) exacerbations, offering hope for improved management of this debilitating lung disease.

Hospitalized older adults infected with SARS-CoV-2 had faster declines in executive function and memory compared with both uninfected and nonhospitalized infected patients.

Emerging trial results reveal gedatolisib significantly enhances progression-free survival (PFS) in advanced HR+/HER2- breast cancer.

FDA places clinical hold on Sarepta's Elevidys gene therapy after safety concerns, but ambulatory patients regain access amid ongoing investigations.

A phase 2 trial shows oxylanthanum carbonate (OLC) effectively manages hyperphosphatemia in patients with chronic kidney disease (CKD), offering a promising treatment option.

A meta-analysis suggests that long-term P2Y12 inhibitor monotherapy after percutaneous coronary intervention may offer superior protection against major adverse cardiac and cerebrovascular events compared with aspirin, without increasing major bleeding risk—potentially challenging current guideline recommendations for antiplatelet therapy beyond 1 year.

Experts discuss HIV management challenges, including HBV coinfections, anal cancer risks, and weight gain, highlighting innovative treatment strategies.

FDA approves lonapegsomatropin for once-weekly treatment of growth hormone deficiency, offering a promising alternative for improved patient adherence and outcomes.

Jeffrey I. Weitz, OC, MD, FAHA, FRCPC, FACP, FRSC, FACC, FESC, FCAHS, discusses AZALEA-TIMI 71 trial data showing that the long-acting factor XI inhibitor abelacimab is associated with low periprocedural bleeding risk, supporting potential simplification of anticoagulation protocols for most elective and some urgent procedures.

VMAT2 inhibitors can improve movement symptoms.

GLP-1 receptor agonists show promise in improving survival rates for older patients with cancer who have type 2 diabetes (T2D), highlighting their potential in oncology.

Targeting BRD4 with BET inhibitors shows promise in reversing immune suppression by myeloid-derived suppressor cells in chronic lymphocytic leukemia.

With cuts to the Department of Health and Human Services incoming, efforts to research, surveil, and prevent infections of Clostridioides difficile could be derailed.

RSV outbreaks pose significant risks globally, highlighting the urgent need for targeted vaccination and treatment strategies to protect vulnerable populations.

Avatrombopag gains FDA approval for pediatric ITP treatment, offering a new oral option for managing chronic thrombocytopenia in children.

Ochsner partners with Latent Health to utilize clinical artificial intelligence (AI), speeding prior authorizations, improving pharmacy efficiency, and increasing patient access to medications.

Cephalosporins are commonly prescribed in the outpatient setting; understanding differences among them is important for pharmacists.

Trastuzumab deruxtecan shows promising efficacy in treating HER2-positive metastatic breast cancer with brain metastases, offering hope for challenging cases.

The decentralization of US health care, accelerated by virtual care adoption, shifting reimbursement models, and a growing demand for complex therapies, is elevating the role of specialty and infusion pharmacies as essential, tech-enabled partners in delivering coordinated, patient-centered care across outpatient and home-based settings.

Finerenone plays an emerging role in managing complex heart failure with preserved ejection fraction (HFpEF).

Immense burden is laid upon patients with cancer who are infected with COVID-19, as they are at higher risk of experiencing cancer treatment disruptions and severe illness that necessitates hospitalization.

Eugene Przespolewski, PharmD, BCOP, DPLA, shares insights from his presentation at the 2025 OPC meeting in Austin, Texas.

New research reveals uranium isotopes in urine as potential biomarkers for kidney damage, highlighting risks from contaminated drinking water in the US.

Pharmacists are pivotal in optimizing GLP-1 receptor agonist therapy.

Carrie Harney, JD, of US Pharmacopeia (USP) discusses how proposed tariffs could impact generic drug supply chains, sterile injectable shortages, and pharmacy operations, underscoring the need for policy incentives and manufacturing diversification.

UPMC Health Plan enhances COPD care through a multidisciplinary approach, leveraging telehealth, education, and pharmacist-led programs to optimize patient outcomes.

Results from the ZENITH trial show sotatercept's promise for pulmonary arterial hypertension treatment.

Omolola (Lola) A. Adeoye-Olatunde, PharmD, MS, discusses her passion for advancing community-engaged pharmacy research.